ibrutinib,obinutuzumab,venetoclax
abbvie,janssen,roche
['cll13', 'cll', 'venetoclax']
highly complex karyotype predicts shorter pfs in ven containing regimens from cll13 (though no impact on os). both int and highly complex karyotype bad in cit. tp53/17p excluded from this trial. #ash22 
Associate clinical professor at UC Irvine focused on CLL/SLL and CHIP/CCUS/MDS. Animal and nature lover. Tweets are my own.